Abstract 2270
Background
Despite a population of over 180 million and over 115,950 new cases of cancer diagnosed every year, Nigeria has no dedicated medical oncologists (MO). Most oncology care is delivered through surgical (SO) and radiation oncologists (RO) who number less than 50 in the entire country. With the limited number of oncology professionals, cancer patients experience poor outcomes, with a less than 10% of 5-year cancer survival rate.
Methods
The participants were nominated by their institutions to attend the medical oncology training. Through the support of FSP and U.S. Embassy in Nigeria, MGM and TOC delivered 10-days of lectures based on ASCO, ESMO and NCCN guidelines in Abuja, Nigeria. Participants represented 15 Nigerian states, including 5 of the 6 ethnic and geographic regions. Mean correct scores of participants that completed both the pre- and post-course 25 question tests (composed by 2 of the authors TOC and MGM) were compared using GraphPad Prism 7.0a by Paired t-tests.
Results
Forty-four oncologists were identified of which 11 (25%) were females. Twenty-five (57%) completed both the pre- and post-tests and fully participated in the 10-day lecture series. 12 participates that completed the training were residents and 12 were attending physicians. One doctor did not identify as a resident or attending. Of the 25 that completed both tests, percentage of correct answers increased from 45% to 59% (2-sided p-value <0.0001). Benefits were seen both with attending doctors 45% to 59% (p = 0.0046) and resident doctors 45% to 59% (0.0007).
Conclusions
MO education coordinated by FSP and PPB improved MO knowledge in Nigeria regardless of participant background. Similar models may be employed across Sub-Saharan Africa. Reasons for lost participation need to be defined.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Project PinkBlue.
Funding
United States of America Department of State.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5043 - Comprehensive results of a Phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer
Presenter: Ursula Wiedermann
Session: Poster Display session 3
Resources:
Abstract
4506 - Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity
Presenter: Adel Samson
Session: Poster Display session 3
Resources:
Abstract
1631 - Randomized phase 2 clinical trial of NY-ESO-1 protein vaccine combined with cholesteryl pullulan (CHP-NY-ESO-1) in resected esophageal cancer patients
Presenter: Shinichi Kageyama
Session: Poster Display session 3
Resources:
Abstract
4244 - T cell repertoire sequencing reveals dynamics of response to dendritic cell vaccine plus dasatinib for checkpoint blockade resistant metastatic melanoma
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
5791 - Ixovex, a novel oncolytic E1B-mutated adenovirus
Presenter: Mohiemen Anwar
Session: Poster Display session 3
Resources:
Abstract
4170 - Anti-CSPG4 DNA vaccination as a promising strategy for the treatment of CSPG4+ tumors: a comparative oncology trial
Presenter: Federica Riccardo
Session: Poster Display session 3
Resources:
Abstract
5780 - Antitumor activity, immunogenicity and safety of a novel PD-1 vaccine in combination with two chimeric HER-2 peptide vaccine in syngeneic Balb/c, C57Bl/6 models and in beagle dogs
Presenter: Pravin Kaumaya
Session: Poster Display session 3
Resources:
Abstract
5860 - Maternal immunization against ALK as a weapon to fight neuroblastoma
Presenter: Giuseppina Barutello
Session: Poster Display session 3
Resources:
Abstract
4720 - Phase 1 study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumors
Presenter: Jason Luke
Session: Poster Display session 3
Resources:
Abstract
5717 - Anti-PD-L1/IL-15 fusion protein generates robust adaptive immune gene signatures in tumors leading to tumor inhibition and memory responses
Presenter: Stella Martomo
Session: Poster Display session 3
Resources:
Abstract